Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials

Springer Science and Business Media LLC - Tập 32 - Trang 181-181 - 2018
Harold E. Bays1, Robert S. Rosenson2, Marie T. Baccara-Dinet3, Michael J. Louie4, Desmond Thompson4, G. Kees Hovingh5
1Departments of Epidemiology & Medicine, Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, USA
2Cardiometabolics Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, USA
3Clinical Development, R&D, Montpellier, France
4Regeneron Pharmaceuticals Inc., Tarrytown, USA
5Department of Vascular Medicine - Internal Medicine Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Tóm tắt

The original version of this article unfortunately contained a mistake in the Discussion section.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 32

181-181

Thông tin tác giả